What is the current Price Target for the aTyr Pharma, Inc. stock?

The average aTyr Pharma, Inc. target price is $18.55. This is 290.53% higher than the current stock price. The highest price target is 636.84%, the lowest is 89.47%. 10 Analysts have issued a price target aTyr Pharma, Inc. 2026 .

How high will the aTyr Pharma, Inc. stock rise?

No reliable answer can be given as to how high the aTyr Pharma, Inc. stock will rise. The performance of stocks, including the aTyr Pharma, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the aTyr Pharma, Inc. stock today?

The performance of aTyr Pharma, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the aTyr Pharma, Inc. stock fall?

The decline in aTyr Pharma, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

aTyr Pharma, Inc. Forecast, price target & analysts

$4.75

6.26% yesterday

Nasdaq, Jun 02, 10:16 pm CET

ISIN

US0021201035

Symbol

ATYR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

aTyr Pharma, Inc. Target price 2025 - Analyst rating & recommendation

aTyr Pharma, Inc. Classifications & Recommendation:

Buy

100%

aTyr Pharma, Inc. Price Target

Target Price	$18.55
Price	$4.75
Potential	290.53% register free of charge
Number of Estimates	10

	10 Analysts have issued a price target aTyr Pharma, Inc. 2026 . The average aTyr Pharma, Inc. target price is $18.55. This is 290.53% register free of charge higher than the current stock price. The highest price target is $35.00 636.84% register free of charge , the lowest is $9.00 89.47% register free of charge .
	A rating was issued by 11 analysts: 11 Analysts recommend aTyr Pharma, Inc. to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the aTyr Pharma, Inc. stock has an average upside potential 2026 of 290.53% register free of charge . Most analysts recommend the aTyr Pharma, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-0.86	-0.66
	8.51%	23.26%
P/E		negative
EV/Sales		171.84

5 Analysts have issued a aTyr Pharma, Inc. forecast for earnings per share. The average aTyr Pharma, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-0.86	8.51%
2025	$-0.66 23.26% Unlock
2026	$-0.67 1.52% Unlock
2027	$-0.35 47.76% Unlock
2028	$0.45 228.57% Unlock
2029	$0.90 100.00% Unlock

Current	-6.51	204.65%
2025	-7.22 10.96% Unlock
2026	-7.13 1.25% Unlock
2027	-13.67 91.73% Unlock
2028	10.56 177.25% Unlock
2029	5.28 50.00% Unlock

aTyr Pharma, Inc....

Current aTyr Pharma, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	May 19 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 14 2025
Leerink Partners	Locked ➜ Locked	Locked	Feb 18 2025
Cantor Fitzgerald	Locked ➜ Locked	Locked	Jan 06 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Dec 10 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Dec 03 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Oct 29 2024

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	May 19 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 14 2025
Locked Leerink Partners: Locked ➜ Locked	Feb 18 2025
Locked Cantor Fitzgerald: Locked ➜ Locked	Jan 06 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Dec 10 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Dec 03 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Oct 29 2024

Discover more stocks with a high price target

NIO ADR 51.46%

Alibaba Group Holding Ltd 39.77%

TUI 37.83%

Novo Nordisk 36.18%

MongoDB 29.93%

Tencent Holdings Ltd. 28.03%

BYD 25.29%

NVIDIA 23.99%

BioNTech SE - ADR 20.70%

Pfizer 19.80%

Adidas 19.39%

Porsche 19.21%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now